Work

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study

Year: 2023

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Rheumatology

DOI: 10.1016/s2665-9913(23)00161-3

Authors: Roy M Fleischmann, Wassim Saikali, Sharad Lakhanpal, Daniel F Alvarez, Donna S Cox, Claudia Ana Ianos, Wuyan Zhang, Carol Cronenberger, Karen Wang

Institutions: Metroplex Clinical Research Center, The University of Texas Southwestern Medical Center, Pfizer (United States), Pfizer (Switzerland)

Language: English

Topic: Biosimilars and Bioanalytical Methods

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4386021188

FWCI: 1.576

Cites: 13

Cited by: 18

Related to: 10